$5 million grant to test Alzheimer’s treatment
Israel’s ImmunoBrain Checkpoint (see here previously) has been awarded a grant of $5 million over 3 years to support human clinical trials of IBC-Ab002, for the treatment of Alzheimer’s disease. Development was based on Weizmann Institute immune system studies.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink